TEMENOS
29.9.2021 10:30:06 CEST | Business Wire | Press release
Temenos (SIX: TEMN), the banking software company, today announced that Temenos Infinity has been awarded "best-in-class" (the highest rating) in the Aite Matrix Evaluation: US Digital Banking Solutions of Core Providers. Temenos edged out six others as the only "best-in-class" vendor in the report. In its analysis, Aite-Novarica (previously Aite Group) recognized Temenos Infinity for its openness, ecosystem of integrated fintech solutions, conversational banking capability, and a forward-looking approach to financial wellness.
Aite-Novarica evaluated the top seven core banking providers in the US that offer a digital banking solution. Out of all the vendors evaluated, Temenos scored the highest in three out of four categories: vendor stability, client strength, and product features, and was joint highest for client services.
Temenos Infinity is available to any financial institution regardless of the core system they have in place. The solution uses APIs to support multiple vendor cores, internally built systems, or Temenos Transact.
David Albertazzi, Director, Retail Banking & Payments Practice, Aite-Novarica Group, commented: "Temenos finished ahead of the competition, demonstrating a strong balance of both vendor strength and product performance. The Temenos Infinity digital banking platform is both feature-rich and UX strong, has the ability to deliver a seamless end-to-end digital journey through a platform approach that connects legacy and fintech partners, and has a more forward-looking vision on financial wellness tools that enables it to stand out from its peers."
Max Chuard, Chief Executive Officer, Temenos, said: "This is a proud achievement that reflects the powerful capability of the Temenos Infinity platform and our commitment to customer success. Temenos Infinity is the world's best-selling digital banking platform used by over 650 financial institutions, from global tier one banks to digital challengers. Today's consumers expect the same kind of responsive experience for their banking needs as they get from the likes of Amazon and Netflix. We are seeing an acceleration in adoption in the US market and with Temenos Infinity, these banks can fulfill their customers' ever-increasing demands for digital services faster and at lower costs."
Temenos Infinity leads the market with groundbreaking innovations, benefitting from Temenos' industry-leading levels of R&D - 20% of annual revenue, more than twice the level of industry competitors. In the last 12 months, Temenos launched Temenos Infinity Virtual COO, a digital solution enabled by Explainable AI that provides data-driven insights and helps banks power SME growth. The company also announced its Micro Apps architecture, making it easier for banks to quickly create personalized digital experiences to serve specific segments, like families or students.
With digitalization an imperative for banks, Temenos Infinity helps banks succeed and grow. It drives exceptional, personal customer experiences by combining digital technology with a human touch. Its advanced analytics drives customer acquisition and digital banking engagement, enabling financial institutions to increase digital revenues 5x and cut customer onboarding time by 75%. Financial institutions that use Temenos Infinity report a 20% higher Net Promoter Score.
Temenos was also recently named a leader in two key reports - The Forrester Wave™: Digital Banking Engagement Platforms and Digital Banking Engagement Hubs evaluations for Q3 2021.
– Ends –
About Temenos
Temenos AG (SIX: TEMN) is the world's leader in banking software. Over 3,000 banks across the globe, including 41 of the top 50 banks, rely on Temenos to process both the daily transactions and client interactions of more than 1.2 billion banking customers. Temenos offers cloud-native, cloud-agnostic and AI-driven front office, core banking, payments and fund administration software enabling banks to deliver frictionless, omnichannel customer experiences and gain operational excellence.
Temenos software is proven to enable its top-performing clients to achieve cost-income ratios of 26.8% half the industry average and returns on equity of 29%, three times the industry average. These clients also invest 51% of their IT budget on growth and innovation versus maintenance, which is double the industry average, proving the banks' IT investment is adding tangible value to their business.
For more information, please visit www.temenos.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210929005384/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SOLUM and Simbe Expand European Collaboration to Advance Intelligent Store Operations5.3.2026 08:00:00 CET | Press release
SOLUM (KOSPI: 248070) and Simbe announced the expansion of their strategic collaboration to further integrate autonomous store intelligence with SOLUM’s Newton Electronic Shelf Label (ESL) infrastructure across Europe. The collaboration was highlighted at EuroShop, where Simbe’s Store Intelligence™ platform was demonstrated live at the SOLUM booth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304620371/en/ SOLUM and Simbe announced the expansion of their strategic collaboration to further integrate autonomous store intelligence with SOLUM’s Newton Electronic Shelf Label (ESL) infrastructure across Europe. (Image: SOLUM) Simbe recently introduced Tally 4.0, the next generation of their autonomous shelf-scanning robot, reflecting the company’s continued evolution in retail shelf digitization, incorporating extended runtime, enhanced edge computing, and advanced vision capabilities. Designed to deliver deeper shelf coverag
Mosaic Clinical Technologies Announces FDA Breakthrough Device Designation for Cognita’s Generative AI Model for Radiology5.3.2026 08:00:00 CET | Press release
Breakthrough designation means Cognita™ will engage in prioritized interaction with FDA regarding clearance of device designed to help solve the radiology capacity bottleneck Mosaic Clinical Technologies™, a wholly-owned subsidiary of Radiology Partners, is pleased to announce that Cognita™, its AI business unit developing generative vision-language models (VLMs) for radiology, has received U.S. Food and Drug Administration (FDA) Breakthrough Device Designation for Cognita Chest X-Ray (CXR)™1 across multiple critical indications. Cognita CXR is an industry-first generative vision-language model designed to assist radiologists in the interpretation of chest X-rays and is the first radiology generative AI model, and one of very few radiology AI solutions, to be granted this designation2. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304633206/en/ Cognita™ operates as the AI business unit of Mosaic Clinical Technologies™, a
Cielo Advances Resilient Remote Connectivity for Its Nationwide Payment Terminal Fleet With Thales5.3.2026 08:00:00 CET | Press release
Cielo, one of Brazil’s leading payment service providers, is piloting remote connectivity management for its point-of-sale (POS) terminals across the country, in partnership with Thales. By deploying Thales’s eSIM connectivity management platform based on the latest GSMA SGP.32 IoT standard, Cielo is accelerating its transition from manual, on-site SIM management to fully remote, secure and resilient connectivity. For Cielo, connectivity is mission critical. When payment terminals lose network access, transactions stop. To strengthen operational resilience and enhance merchant experience, Cielo is modernizing its connectivity architecture across its terminal fleet. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304089321/en/ Cielo advances resilient remote connectivity for its nationwide payment terminal fleet with Thales. Using Thales’s eSIM technology as part of this strategy, Cielo can remotely switch mobile network op
GAIA and Daiichi Sankyo Europe Enter Exclusive Partnership to Launch Next-Generation Digital Therapeutic for Cardiovascular Care in Europe.5.3.2026 08:00:00 CET | Press release
GAIA, the pioneer in evidence-based digital therapeutics and Daiichi Sankyo Europe, today announced an exclusive strategic partnership to commercialize lipodia upon regulatory approval1. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224658973/en/ Dr. Mario Weiss, Founder & CEO of GAIA AG This digital therapeutic is designed to support adults living with hypercholesterolemia. The comprehensive collaboration brings together GAIA’s long-standing expertise in developing clinically validated non-pharmacological interventions with Daiichi Sankyo’s highly scientific experience in cardiovascular risk management and health. Together, the partners - both members of the German Association of Research-Based Pharmaceutical Companies (vfa) - aim to address a persistent gap in chronic care: leveraging digital technologies to make a difference in patients’ lives by supporting sustainable, long-term behaviour change. Expanding Cardiovasc
Galderma Delivers Record 2025 Results With Net Sales of 5.207 Billion USD, up 17.7% at Constant Currency1, and Core EBITDA2 of 1.211 billion USD, Growing 18.9% at Constant Currency5.3.2026 07:00:00 CET | Press release
Ad hoc announcement pursuant to Art. 53 LR Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its financial results for the full year 2025. Record net sales of 5,207 million USD, surpassing 5 billion USD in a year for the first time and representing 17.7% year-on-year growth on a constant currency1 basis, primarily driven by volume. Broad-based net sales growth, growing double-digits in both International markets and the U.S. Outperforming the market in each product category, with strong net sales growth in Injectable Aesthetics (11.5%), Dermatological Skincare (9.3%) and Therapeutic Dermatology (50.2%), all year-on-year at constant currency. Strong launch momentum across future growth drivers, including Nemluvio® (nemolizumab) delivering 452 million USD in net sales; Relfydess™ (RelabotulinumtoxinA) outperforming expectations in 17 International markets; Sculptra® gaining significant market share in its first year in China; and continued new produ
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
